Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Melatonin receptors are a class of G-protein coupled receptors (GPCRs) that mediate the physiological effects of melatonin, a hormone primarily involved in regulating circadian rhythms and sleep-wake cycles. The two main subtypes in humans are MT1 and MT2. MT1 is primarily involved in sleep initiation and maintenance, vasoconstriction, and inhibition of prolactin secretion. MT2 mediates phase-shifting effects on circadian rhythms, promotes vasodilation, regulates retinal physiology and osteoblast function, and is associated with anxiolytic effects. Both subtypes act via Gi/o proteins, leading to inhibition of adenylate cyclase activity and reduced cAMP levels. They are targets for drugs treating insomnia, sleep disorders, and neuropsychiatric conditions.
Agonism or antagonism of MT1 and/or MT2 receptors, leading to modulation of downstream signaling pathways primarily involving inhibition of adenylate cyclase and reduced cAMP levels.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Melatonin Receptor (None).